Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010374 | 0.74 | KMO (0.44) | — | |
| SCHEMBL8205755 | 0.70 | TRPA1 (0.43) | — | |
| SCHEMBL830187 | 0.70 | CYP1A2 (0.37) | PARP1NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL28652832 | 0.69 | CYP1A2 (0.36) | NOS1NOS2 | |
| SCHEMBL27570322 | 0.68 | LMNA (0.47) | MPO | |
| Ammonia Solution, Strong SCHEMBL11451734 | 0.67 | CYP1A2 (0.35) | NOS1NOS2 | |
| SCHEMBL14402511 | 0.67 | BACE1 (0.40) | DHFR | |
| SCHEMBL8228105 | 0.66 | GABRA1 (0.52) | — | |
| SCHEMBL21883855 | 0.66 | LOXL2 (0.38) | PARP1NOS1NOS2 | |
| SCHEMBL21087162 | 0.66 | MPO (0.35) | MPOKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662189-B2 | PDE4 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190177318-A1 | PDE4 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177318-A1 | PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | DHFR 377/4885KDM5A 1037/4885KDM5B 1118/4885 |
| US-10662189-B2 | PDE4 inhibitor | PDE4A, PDE12, PDE4B | DHFR 377/4885KDM5A 1037/4885KDM5B 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.